News Vtesse's rare disease drug set for UK early access Vtesse drug "promising" treatment for NPC disease, says regulator.
News Lilly's triple agonist retatrutide passes diabetes test Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
